1167-P: Safety and Efficacy of 52 Weeks' Therapy with Hydroxychloroquine (HCQ)—First Anti-inflammatory Drug Approved in India for T2D
2019 ◽
Vol 68
(Supplement 1)
◽
pp. 1167-P
ANIL PAREEK
◽
RAVI TEJRAJ MEHTA
◽
SHRUTI DHARMADHIKARI
◽
KUMAR BHASKAR NAIDU